Global RNAi for Therapeutic Supply, Demand and Key Producers, 2024-2030

Description

The global RNAi for Therapeutic market size is expected to reach $ 2031.2 million by 2030, rising at a market growth of 41.2% CAGR during the forecast period (2024-2030).

Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.

US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.

In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

This report studies the global RNAi for Therapeutic demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for RNAi for Therapeutic, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of RNAi for Therapeutic that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global RNAi for Therapeutic total market, 2019-2030, (USD Million)
Global RNAi for Therapeutic total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: RNAi for Therapeutic total market, key domestic companies and share, (USD Million)
Global RNAi for Therapeutic revenue by player and market share 2019-2024, (USD Million)
Global RNAi for Therapeutic total market by Type, CAGR, 2019-2030, (USD Million)
Global RNAi for Therapeutic total market by Application, CAGR, 2019-2030, (USD Million).

This reports profiles major players in the global RNAi for Therapeutic market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, Quark Pharmaceuticals, RXi Pharmaceuticals, Silence Therapeutics and Benitec Biopharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World RNAi for Therapeutic market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global RNAi for Therapeutic Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global RNAi for Therapeutic Market, Segmentation by Type
    siRNA
    miRNA
    shRNA

Global RNAi for Therapeutic Market, Segmentation by Application
    Cancer
    Cardiovascular
    HBV
    Others

Companies Profiled:
    Alnylam Pharmaceuticals
    Arbutus Biopharma (Tekmira)
    Arrowhead
    Dicerna Pharmaceuticals
    Mirna Therapeutics
    Quark Pharmaceuticals
    RXi Pharmaceuticals
    Silence Therapeutics
    Benitec Biopharma
    miRagen Therapeutics
    Sylentis
    Gradalis
    Sirnaomics
    Silenseed

Key Questions Answered
1. How big is the global RNAi for Therapeutic market?
2. What is the demand of the global RNAi for Therapeutic market?
3. What is the year over year growth of the global RNAi for Therapeutic market?
4. What is the total value of the global RNAi for Therapeutic market?
5. Who are the major players in the global RNAi for Therapeutic market?

Table of Contents

1 Supply Summary
    1.1 RNAi for Therapeutic Introduction
    1.2 World RNAi for Therapeutic Market Size & Forecast (2019 & 2023 & 2030)
    1.3 World RNAi for Therapeutic Total Market by Region (by Headquarter Location)
        1.3.1 World RNAi for Therapeutic Market Size by Region (2019-2030), (by Headquarter Location)
        1.3.2 United States RNAi for Therapeutic Market Size (2019-2030)
        1.3.3 China RNAi for Therapeutic Market Size (2019-2030)
        1.3.4 Europe RNAi for Therapeutic Market Size (2019-2030)
        1.3.5 Japan RNAi for Therapeutic Market Size (2019-2030)
        1.3.6 South Korea RNAi for Therapeutic Market Size (2019-2030)
        1.3.7 ASEAN RNAi for Therapeutic Market Size (2019-2030)
        1.3.8 India RNAi for Therapeutic Market Size (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 RNAi for Therapeutic Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 RNAi for Therapeutic Major Market Trends

2 Demand Summary
    2.1 World RNAi for Therapeutic Consumption Value (2019-2030)
    2.2 World RNAi for Therapeutic Consumption Value by Region
        2.2.1 World RNAi for Therapeutic Consumption Value by Region (2019-2024)
        2.2.2 World RNAi for Therapeutic Consumption Value Forecast by Region (2025-2030)
    2.3 United States RNAi for Therapeutic Consumption Value (2019-2030)
    2.4 China RNAi for Therapeutic Consumption Value (2019-2030)
    2.5 Europe RNAi for Therapeutic Consumption Value (2019-2030)
    2.6 Japan RNAi for Therapeutic Consumption Value (2019-2030)
    2.7 South Korea RNAi for Therapeutic Consumption Value (2019-2030)
    2.8 ASEAN RNAi for Therapeutic Consumption Value (2019-2030)
    2.9 India RNAi for Therapeutic Consumption Value (2019-2030)

3 World RNAi for Therapeutic Companies Competitive Analysis
    3.1 World RNAi for Therapeutic Revenue by Player (2019-2024)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global RNAi for Therapeutic Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for RNAi for Therapeutic in 2023
        3.2.3 Global Concentration Ratios (CR8) for RNAi for Therapeutic in 2023
    3.3 RNAi for Therapeutic Company Evaluation Quadrant
    3.4 RNAi for Therapeutic Market: Overall Company Footprint Analysis
        3.4.1 RNAi for Therapeutic Market: Region Footprint
        3.4.2 RNAi for Therapeutic Market: Company Product Type Footprint
        3.4.3 RNAi for Therapeutic Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: RNAi for Therapeutic Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: RNAi for Therapeutic Market Size Comparison (2019 & 2023 & 2030) (by Headquarter Location)
        4.1.2 United States VS China: RNAi for Therapeutic Revenue Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States Based Companies VS China Based Companies: RNAi for Therapeutic Consumption Value Comparison
        4.2.1 United States VS China: RNAi for Therapeutic Consumption Value Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: RNAi for Therapeutic Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States Based RNAi for Therapeutic Companies and Market Share, 2019-2024
        4.3.1 United States Based RNAi for Therapeutic Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies RNAi for Therapeutic Revenue, (2019-2024)
    4.4 China Based Companies RNAi for Therapeutic Revenue and Market Share, 2019-2024
        4.4.1 China Based RNAi for Therapeutic Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies RNAi for Therapeutic Revenue, (2019-2024)
    4.5 Rest of World Based RNAi for Therapeutic Companies and Market Share, 2019-2024
        4.5.1 Rest of World Based RNAi for Therapeutic Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies RNAi for Therapeutic Revenue, (2019-2024)

5 Market Analysis by Type
    5.1 World RNAi for Therapeutic Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 siRNA
        5.2.2 miRNA
        5.2.3 shRNA
    5.3 Market Segment by Type
        5.3.1 World RNAi for Therapeutic Market Size by Type (2019-2024)
        5.3.2 World RNAi for Therapeutic Market Size by Type (2025-2030)
        5.3.3 World RNAi for Therapeutic Market Size Market Share by Type (2019-2030)

6 Market Analysis by Application
    6.1 World RNAi for Therapeutic Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Cancer
        6.2.2 Cardiovascular
        6.2.3 HBV
        6.2.4 Others
        6.2.5 Others
    6.3 Market Segment by Application
        6.3.1 World RNAi for Therapeutic Market Size by Application (2019-2024)
        6.3.2 World RNAi for Therapeutic Market Size by Application (2025-2030)
        6.3.3 World RNAi for Therapeutic Market Size by Application (2019-2030)

7 Company Profiles
    7.1 Alnylam Pharmaceuticals
        7.1.1 Alnylam Pharmaceuticals Details
        7.1.2 Alnylam Pharmaceuticals Major Business
        7.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Product and Services
        7.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.1.5 Alnylam Pharmaceuticals Recent Developments/Updates
        7.1.6 Alnylam Pharmaceuticals Competitive Strengths & Weaknesses
    7.2 Arbutus Biopharma (Tekmira)
        7.2.1 Arbutus Biopharma (Tekmira) Details
        7.2.2 Arbutus Biopharma (Tekmira) Major Business
        7.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Services
        7.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.2.5 Arbutus Biopharma (Tekmira) Recent Developments/Updates
        7.2.6 Arbutus Biopharma (Tekmira) Competitive Strengths & Weaknesses
    7.3 Arrowhead
        7.3.1 Arrowhead Details
        7.3.2 Arrowhead Major Business
        7.3.3 Arrowhead RNAi for Therapeutic Product and Services
        7.3.4 Arrowhead RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.3.5 Arrowhead Recent Developments/Updates
        7.3.6 Arrowhead Competitive Strengths & Weaknesses
    7.4 Dicerna Pharmaceuticals
        7.4.1 Dicerna Pharmaceuticals Details
        7.4.2 Dicerna Pharmaceuticals Major Business
        7.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Product and Services
        7.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.4.5 Dicerna Pharmaceuticals Recent Developments/Updates
        7.4.6 Dicerna Pharmaceuticals Competitive Strengths & Weaknesses
    7.5 Mirna Therapeutics
        7.5.1 Mirna Therapeutics Details
        7.5.2 Mirna Therapeutics Major Business
        7.5.3 Mirna Therapeutics RNAi for Therapeutic Product and Services
        7.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.5.5 Mirna Therapeutics Recent Developments/Updates
        7.5.6 Mirna Therapeutics Competitive Strengths & Weaknesses
    7.6 Quark Pharmaceuticals
        7.6.1 Quark Pharmaceuticals Details
        7.6.2 Quark Pharmaceuticals Major Business
        7.6.3 Quark Pharmaceuticals RNAi for Therapeutic Product and Services
        7.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.6.5 Quark Pharmaceuticals Recent Developments/Updates
        7.6.6 Quark Pharmaceuticals Competitive Strengths & Weaknesses
    7.7 RXi Pharmaceuticals
        7.7.1 RXi Pharmaceuticals Details
        7.7.2 RXi Pharmaceuticals Major Business
        7.7.3 RXi Pharmaceuticals RNAi for Therapeutic Product and Services
        7.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.7.5 RXi Pharmaceuticals Recent Developments/Updates
        7.7.6 RXi Pharmaceuticals Competitive Strengths & Weaknesses
    7.8 Silence Therapeutics
        7.8.1 Silence Therapeutics Details
        7.8.2 Silence Therapeutics Major Business
        7.8.3 Silence Therapeutics RNAi for Therapeutic Product and Services
        7.8.4 Silence Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.8.5 Silence Therapeutics Recent Developments/Updates
        7.8.6 Silence Therapeutics Competitive Strengths & Weaknesses
    7.9 Benitec Biopharma
        7.9.1 Benitec Biopharma Details
        7.9.2 Benitec Biopharma Major Business
        7.9.3 Benitec Biopharma RNAi for Therapeutic Product and Services
        7.9.4 Benitec Biopharma RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.9.5 Benitec Biopharma Recent Developments/Updates
        7.9.6 Benitec Biopharma Competitive Strengths & Weaknesses
    7.10 miRagen Therapeutics
        7.10.1 miRagen Therapeutics Details
        7.10.2 miRagen Therapeutics Major Business
        7.10.3 miRagen Therapeutics RNAi for Therapeutic Product and Services
        7.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.10.5 miRagen Therapeutics Recent Developments/Updates
        7.10.6 miRagen Therapeutics Competitive Strengths & Weaknesses
    7.11 Sylentis
        7.11.1 Sylentis Details
        7.11.2 Sylentis Major Business
        7.11.3 Sylentis RNAi for Therapeutic Product and Services
        7.11.4 Sylentis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.11.5 Sylentis Recent Developments/Updates
        7.11.6 Sylentis Competitive Strengths & Weaknesses
    7.12 Gradalis
        7.12.1 Gradalis Details
        7.12.2 Gradalis Major Business
        7.12.3 Gradalis RNAi for Therapeutic Product and Services
        7.12.4 Gradalis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.12.5 Gradalis Recent Developments/Updates
        7.12.6 Gradalis Competitive Strengths & Weaknesses
    7.13 Sirnaomics
        7.13.1 Sirnaomics Details
        7.13.2 Sirnaomics Major Business
        7.13.3 Sirnaomics RNAi for Therapeutic Product and Services
        7.13.4 Sirnaomics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.13.5 Sirnaomics Recent Developments/Updates
        7.13.6 Sirnaomics Competitive Strengths & Weaknesses
    7.14 Silenseed
        7.14.1 Silenseed Details
        7.14.2 Silenseed Major Business
        7.14.3 Silenseed RNAi for Therapeutic Product and Services
        7.14.4 Silenseed RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
        7.14.5 Silenseed Recent Developments/Updates
        7.14.6 Silenseed Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 RNAi for Therapeutic Industry Chain
    8.2 RNAi for Therapeutic Upstream Analysis
    8.3 RNAi for Therapeutic Midstream Analysis
    8.4 RNAi for Therapeutic Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World RNAi for Therapeutic Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
    Table 2. World RNAi for Therapeutic Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
    Table 3. World RNAi for Therapeutic Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
    Table 4. World RNAi for Therapeutic Revenue Market Share by Region (2019-2024), (by Headquarter Location)
    Table 5. World RNAi for Therapeutic Revenue Market Share by Region (2025-2030), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World RNAi for Therapeutic Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
    Table 8. World RNAi for Therapeutic Consumption Value by Region (2019-2024) & (USD Million)
    Table 9. World RNAi for Therapeutic Consumption Value Forecast by Region (2025-2030) & (USD Million)
    Table 10. World RNAi for Therapeutic Revenue by Player (2019-2024) & (USD Million)
    Table 11. Revenue Market Share of Key RNAi for Therapeutic Players in 2023
    Table 12. World RNAi for Therapeutic Industry Rank of Major Player, Based on Revenue in 2023
    Table 13. Global RNAi for Therapeutic Company Evaluation Quadrant
    Table 14. Head Office of Key RNAi for Therapeutic Player
    Table 15. RNAi for Therapeutic Market: Company Product Type Footprint
    Table 16. RNAi for Therapeutic Market: Company Product Application Footprint
    Table 17. RNAi for Therapeutic Mergers & Acquisitions Activity
    Table 18. United States VS China RNAi for Therapeutic Market Size Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 19. United States VS China RNAi for Therapeutic Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 20. United States Based RNAi for Therapeutic Companies, Headquarters (States, Country)
    Table 21. United States Based Companies RNAi for Therapeutic Revenue, (2019-2024) & (USD Million)
    Table 22. United States Based Companies RNAi for Therapeutic Revenue Market Share (2019-2024)
    Table 23. China Based RNAi for Therapeutic Companies, Headquarters (Province, Country)
    Table 24. China Based Companies RNAi for Therapeutic Revenue, (2019-2024) & (USD Million)
    Table 25. China Based Companies RNAi for Therapeutic Revenue Market Share (2019-2024)
    Table 26. Rest of World Based RNAi for Therapeutic Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies RNAi for Therapeutic Revenue, (2019-2024) & (USD Million)
    Table 28. Rest of World Based Companies RNAi for Therapeutic Revenue Market Share (2019-2024)
    Table 29. World RNAi for Therapeutic Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Table 30. World RNAi for Therapeutic Market Size by Type (2019-2024) & (USD Million)
    Table 31. World RNAi for Therapeutic Market Size by Type (2025-2030) & (USD Million)
    Table 32. World RNAi for Therapeutic Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Table 33. World RNAi for Therapeutic Market Size by Application (2019-2024) & (USD Million)
    Table 34. World RNAi for Therapeutic Market Size by Application (2025-2030) & (USD Million)
    Table 35. Alnylam Pharmaceuticals Basic Information, Area Served and Competitors
    Table 36. Alnylam Pharmaceuticals Major Business
    Table 37. Alnylam Pharmaceuticals RNAi for Therapeutic Product and Services
    Table 38. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 39. Alnylam Pharmaceuticals Recent Developments/Updates
    Table 40. Alnylam Pharmaceuticals Competitive Strengths & Weaknesses
    Table 41. Arbutus Biopharma (Tekmira) Basic Information, Area Served and Competitors
    Table 42. Arbutus Biopharma (Tekmira) Major Business
    Table 43. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Services
    Table 44. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 45. Arbutus Biopharma (Tekmira) Recent Developments/Updates
    Table 46. Arbutus Biopharma (Tekmira) Competitive Strengths & Weaknesses
    Table 47. Arrowhead Basic Information, Area Served and Competitors
    Table 48. Arrowhead Major Business
    Table 49. Arrowhead RNAi for Therapeutic Product and Services
    Table 50. Arrowhead RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 51. Arrowhead Recent Developments/Updates
    Table 52. Arrowhead Competitive Strengths & Weaknesses
    Table 53. Dicerna Pharmaceuticals Basic Information, Area Served and Competitors
    Table 54. Dicerna Pharmaceuticals Major Business
    Table 55. Dicerna Pharmaceuticals RNAi for Therapeutic Product and Services
    Table 56. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 57. Dicerna Pharmaceuticals Recent Developments/Updates
    Table 58. Dicerna Pharmaceuticals Competitive Strengths & Weaknesses
    Table 59. Mirna Therapeutics Basic Information, Area Served and Competitors
    Table 60. Mirna Therapeutics Major Business
    Table 61. Mirna Therapeutics RNAi for Therapeutic Product and Services
    Table 62. Mirna Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 63. Mirna Therapeutics Recent Developments/Updates
    Table 64. Mirna Therapeutics Competitive Strengths & Weaknesses
    Table 65. Quark Pharmaceuticals Basic Information, Area Served and Competitors
    Table 66. Quark Pharmaceuticals Major Business
    Table 67. Quark Pharmaceuticals RNAi for Therapeutic Product and Services
    Table 68. Quark Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 69. Quark Pharmaceuticals Recent Developments/Updates
    Table 70. Quark Pharmaceuticals Competitive Strengths & Weaknesses
    Table 71. RXi Pharmaceuticals Basic Information, Area Served and Competitors
    Table 72. RXi Pharmaceuticals Major Business
    Table 73. RXi Pharmaceuticals RNAi for Therapeutic Product and Services
    Table 74. RXi Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 75. RXi Pharmaceuticals Recent Developments/Updates
    Table 76. RXi Pharmaceuticals Competitive Strengths & Weaknesses
    Table 77. Silence Therapeutics Basic Information, Area Served and Competitors
    Table 78. Silence Therapeutics Major Business
    Table 79. Silence Therapeutics RNAi for Therapeutic Product and Services
    Table 80. Silence Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 81. Silence Therapeutics Recent Developments/Updates
    Table 82. Silence Therapeutics Competitive Strengths & Weaknesses
    Table 83. Benitec Biopharma Basic Information, Area Served and Competitors
    Table 84. Benitec Biopharma Major Business
    Table 85. Benitec Biopharma RNAi for Therapeutic Product and Services
    Table 86. Benitec Biopharma RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 87. Benitec Biopharma Recent Developments/Updates
    Table 88. Benitec Biopharma Competitive Strengths & Weaknesses
    Table 89. miRagen Therapeutics Basic Information, Area Served and Competitors
    Table 90. miRagen Therapeutics Major Business
    Table 91. miRagen Therapeutics RNAi for Therapeutic Product and Services
    Table 92. miRagen Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 93. miRagen Therapeutics Recent Developments/Updates
    Table 94. miRagen Therapeutics Competitive Strengths & Weaknesses
    Table 95. Sylentis Basic Information, Area Served and Competitors
    Table 96. Sylentis Major Business
    Table 97. Sylentis RNAi for Therapeutic Product and Services
    Table 98. Sylentis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 99. Sylentis Recent Developments/Updates
    Table 100. Sylentis Competitive Strengths & Weaknesses
    Table 101. Gradalis Basic Information, Area Served and Competitors
    Table 102. Gradalis Major Business
    Table 103. Gradalis RNAi for Therapeutic Product and Services
    Table 104. Gradalis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 105. Gradalis Recent Developments/Updates
    Table 106. Gradalis Competitive Strengths & Weaknesses
    Table 107. Sirnaomics Basic Information, Area Served and Competitors
    Table 108. Sirnaomics Major Business
    Table 109. Sirnaomics RNAi for Therapeutic Product and Services
    Table 110. Sirnaomics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 111. Sirnaomics Recent Developments/Updates
    Table 112. Silenseed Basic Information, Area Served and Competitors
    Table 113. Silenseed Major Business
    Table 114. Silenseed RNAi for Therapeutic Product and Services
    Table 115. Silenseed RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 116. Global Key Players of RNAi for Therapeutic Upstream (Raw Materials)
    Table 117. RNAi for Therapeutic Typical Customers
List of Figure
    Figure 1. RNAi for Therapeutic Picture
    Figure 2. World RNAi for Therapeutic Total Market Size: 2019 & 2023 & 2030, (USD Million)
    Figure 3. World RNAi for Therapeutic Total Market Size (2019-2030) & (USD Million)
    Figure 4. World RNAi for Therapeutic Revenue Market Share by Region (2019, 2023 and 2030) & (USD Million) , (by Headquarter Location)
    Figure 5. World RNAi for Therapeutic Revenue Market Share by Region (2019-2030), (by Headquarter Location)
    Figure 6. United States Based Company RNAi for Therapeutic Revenue (2019-2030) & (USD Million)
    Figure 7. China Based Company RNAi for Therapeutic Revenue (2019-2030) & (USD Million)
    Figure 8. Europe Based Company RNAi for Therapeutic Revenue (2019-2030) & (USD Million)
    Figure 9. Japan Based Company RNAi for Therapeutic Revenue (2019-2030) & (USD Million)
    Figure 10. South Korea Based Company RNAi for Therapeutic Revenue (2019-2030) & (USD Million)
    Figure 11. ASEAN Based Company RNAi for Therapeutic Revenue (2019-2030) & (USD Million)
    Figure 12. India Based Company RNAi for Therapeutic Revenue (2019-2030) & (USD Million)
    Figure 13. RNAi for Therapeutic Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World RNAi for Therapeutic Consumption Value (2019-2030) & (USD Million)
    Figure 16. World RNAi for Therapeutic Consumption Value Market Share by Region (2019-2030)
    Figure 17. United States RNAi for Therapeutic Consumption Value (2019-2030) & (USD Million)
    Figure 18. China RNAi for Therapeutic Consumption Value (2019-2030) & (USD Million)
    Figure 19. Europe RNAi for Therapeutic Consumption Value (2019-2030) & (USD Million)
    Figure 20. Japan RNAi for Therapeutic Consumption Value (2019-2030) & (USD Million)
    Figure 21. South Korea RNAi for Therapeutic Consumption Value (2019-2030) & (USD Million)
    Figure 22. ASEAN RNAi for Therapeutic Consumption Value (2019-2030) & (USD Million)
    Figure 23. India RNAi for Therapeutic Consumption Value (2019-2030) & (USD Million)
    Figure 24. Producer Shipments of RNAi for Therapeutic by Player Revenue ($MM) and Market Share (%): 2023
    Figure 25. Global Four-firm Concentration Ratios (CR4) for RNAi for Therapeutic Markets in 2023
    Figure 26. Global Four-firm Concentration Ratios (CR8) for RNAi for Therapeutic Markets in 2023
    Figure 27. United States VS China: RNAi for Therapeutic Revenue Market Share Comparison (2019 & 2023 & 2030)
    Figure 28. United States VS China: RNAi for Therapeutic Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    Figure 29. World RNAi for Therapeutic Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Figure 30. World RNAi for Therapeutic Market Size Market Share by Type in 2023
    Figure 31. siRNA
    Figure 32. miRNA
    Figure 33. shRNA
    Figure 34. World RNAi for Therapeutic Market Size Market Share by Type (2019-2030)
    Figure 35. World RNAi for Therapeutic Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Figure 36. World RNAi for Therapeutic Market Size Market Share by Application in 2023
    Figure 37. Cancer
    Figure 38. Cardiovascular
    Figure 39. HBV
    Figure 40. Others
    Figure 41. RNAi for Therapeutic Industrial Chain
    Figure 42. Methodology
    Figure 43. Research Process and Data Source

Companies Mentioned

Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed